Viridans Group Streptococci in Pediatric Leukemia and Stem Cell Transplant: Review of a Risk-stratified Guideline for Empiric Vancomycin in Febrile Neutropenia

Sandra D. Ruhayel, David A. Foley, Kate Hamilton, Patricia Ferguson, Rishi S. Kotecha, Asha C. Bowen, Daniel K. Yeoh

Research output: Contribution to journalArticlepeer-review

Abstract

Viridans group streptococci (VGS) are an important cause of sepsis in immunosuppressed children. We reviewed the effectiveness of risk-stratified addition of vancomycin to empiric febrile neutropenia therapy among 107 children with leukemia or undergoing an allogeneic transplant. Of 19 VGS bacteremia episodes, 78.9% were susceptible to risk-stratified antibiotics including 100% from high-risk patients. All blood cultures were flagged positive within 24 hours.

Original languageEnglish
Pages (from-to)832-834
Number of pages3
JournalPediatric Infectious Disease Journal
Volume40
Issue number9
DOIs
Publication statusPublished - Sep 2021

Fingerprint

Dive into the research topics of 'Viridans Group Streptococci in Pediatric Leukemia and Stem Cell Transplant: Review of a Risk-stratified Guideline for Empiric Vancomycin in Febrile Neutropenia'. Together they form a unique fingerprint.

Cite this